%0 Journal Article %T [Efficacy assessment of Nutrilarm®, a per os omega-3 and omega-6 polyunsaturated essential fatty acid dietary formulation versus placebo in patients with bilateral treated moderate dry eye syndrome]. %+ Service d'Ophtalmologie (CHU de Dijon) %+ Centre des Sciences du Goût et de l'Alimentation [Dijon] (CSGA) %A Creuzot-Garcher, C. %A Baudouin, C. %A Labetoulle, M. %A Pisella, P.-J. %A Mouriaux, Frédéric %A Meddeb-Ouertani, A. %A El Matri, L. %A Khairallah, M. %A Brignole-Baudouin, F. %< avec comité de lecture %@ 0181-5512 %J Journal Français d'Ophtalmologie %I Elsevier Masson %V 34 %N 7 %P 448-55 %8 2011-09 %D 2011 %R 10.1016/j.jfo.2011.01.018 %M 21696849 %K Syndrome de sécheresse oculaire %K Oméga 3 %K Oméga 6 %K Nutrition Dry eye syndrome %K Omega-3 %K Omega-6 %K Nutrition %Z Life Sciences [q-bio]/Human health and pathology/Sensory OrgansJournal articles %X INTRODUCTION: Inflammation is one of the main mechanisms common to all forms of dry eye. Since polyunsaturated acids are known to show biological anti-inflammatory properties, the aim of this study was to evaluate the efficacy of dietary n-6 and n-3 fatty acids in patients suffering from ocular dryness. PATIENTS AND METHODS: One hundred and eighty-one patients diagnosed with bilateral moderate dry eye who were already treated with lachrymal substitutes were randomized in a double-blind international study to receive placebo or Nutrilarm(®) capsules (combination of omega-3 and omega-6), twice a day for 6 months. In all subjects, dryness feeling, overall subjective comfort, and ocular symptoms (burning, stinging, sandy and/or gritty sensation, light sensitivity, reflex tearing, and ocular fatigue) were evaluated at each visit. Furthermore, fluorescein tests (break-uptime and Oxford scheme) and lissamine green test were performed at each visit. The Schirmer test was performed at inclusion and after 6 months of treatment. RESULTS: After 6 months of supplementation with Nutrilarm(®), both the BUT scores and ocular fatigue were significantly improved when compared with placebo (P=0.036 and P=0.044, respectively). There was a trend in favor of Nutrilarm(®) in terms of the efficacy evaluated by the investigator (P=0.061). Fewer patients experienced a feeling of severe dryness with Nutrilarm(®) compared with placebo after 6 months of treatment (2.5 and 9.3%, respectively), but the difference was not statistically significant. CONCLUSION: Oral administration of a double supplementation dietary n-6 and n-3 fatty acids present an additional therapeutic advantage in patients suffering from ocular dryness who were already treated with lachrymal substitutes. %G French %L hal-00684118 %U https://u-bourgogne.hal.science/hal-00684118 %~ UNIV-BOURGOGNE %~ CNRS %~ INRA %~ AGREENIUM %~ INRAE